Piper Jaffray analyst David Amsellem reiterated a Buy rating on Eagle Pharmaceuticals Inc (NASDAQ: EGRX) yesterday and set a price target of $88. The company’s shares closed yesterday at $77.40.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -1.2% and a 45.8% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Supernus Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Eagle Pharmaceuticals Inc is a Strong Buy with an average price target of $76.25, implying a -1.5% downside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $81 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $85.66 and a one-year low of $45.05. Currently, Eagle Pharmaceuticals Inc has an average volume of 253.8K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EGRX in relation to earlier this year. Last month, Scott Tarriff, the CEO of EGRX bought 124,804 shares for a total of $504,208.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban; ryanodex; docetaxel injection, non-alcohol formulation; and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
